September 04, 2020
Despite previous literature documenting cardiovascular disease comorbidity in patients with narcolepsy, pitolisant treatment did not demonstrate any cardiac safety signals.
September 01, 2020
The FDA-approved agent showed significant impact in decreasing standard deviation of lateral position, a measure used to assess driving performance.
September 01, 2020
Pooled data from 2 clinical trials of the H3-receptor antagonist/inverse agonist show it improved cataplexy and excessive daytime sleepiness in patients with narcolepsy who were most hampered by symptoms.
September 01, 2020
Already FDA approved for the treatment of insomnia in adults, lemborexant’s ability to improve sleep outcomes in the elderly was highlighted in a study presented at SLEEP 2020.
August 27, 2020
Benefit from lemborexant was evident after 1 month of switching from placebo to the active treatment and was sustained through the entirety of the 12-month trial.
August 27, 2020
Multiple abstracts at SLEEP 2020 show CBT-I’s success in aiding women with insomnia, including those going through pregnancy, and those who are veterans both with and without PTSD.
June 19, 2019
The director of the center for circadian and sleep medicine at Northwestern University spoke about the importance of recognizing insomnia as a clinical diagnosis since it affects patients 24-hours a day, not just during sleep.
June 13, 2019
All told, every patient with RLS in the study had SIBO present, in comparison to general population rates which range from roughly 6% to greater than 15%.
June 12, 2019
Use of prescription antidepressants and hypnotics was significantly reduced in patients who underwent digital cognitive behavioral therapy for insomnia.
June 12, 2019
The director of the Sleep-Wake Disorders Center at Montefiore Medical Center spoke about the challenges in diagnosing narcolepsy, which often adds to the delay of diagnosis.